Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept & continue
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Alarm mounts in western capitals over Turkey’s deepening ties with Russia
    • US Senate passes Joe Biden’s flagship economic package
    • Chinese aircraft simulate attack on Taiwan’s main island
    • Japan has ‘once-in-lifetime’ chance to end deflation, says departing BoJ official
    • US allies rattled by China’s aggressive response to Nancy Pelosi’s Taiwan visit
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Warren Buffett’s Berkshire reins in stock purchases and books $43.8bn loss
      • US banks tout fossil fuel credentials after Republican ESG backlash
      • Climate, war and inflation jolt reinsurers into action
      • Private equity units at buyout firms contract as financial markets tumble
      • Investors sell stakes in buyout funds at a record pace
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
      Most Read
      • The west’s phantom energy sanctions fuel Russia’s war machine
      • US banks tout fossil fuel credentials after Republican ESG backlash
      • Bank of England accused of failures on shadow banking
      • Investors sell stakes in buyout funds at a record pace
      • Carmakers face fierce battle for lithium until 2030, warns top producer
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Disengaged, indifferent, deluded? Why young workers have an image problem
      • The west’s phantom energy sanctions fuel Russia’s war machine
      • The US and China are decoupling, but not as fast as you think
      • The thirst for freedom in Belarus is unquenchable
      • The Tories risk forgetting a rich tradition of economic thinking
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Brompton’s Will Butler-Adams: ‘People have no idea what goes into a product. That’s not a good thing’
      • Can a city be redesigned for the new world of work?
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Monumental Angkor Wat and the lost ruins of Cambodia
      • The genius of the uncool vacation
      • Nazanin Zaghari-Ratcliffe: ‘I don’t know how I survived’
      • The anxious generation — what’s bothering Britain’s schoolchildren?
      • In 50 years, will anyone still live in central Spain?
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Your guide to a disrupted world

    Start a 4-week trial

    Jamie Smyth

    US Pharmaceutical Correspondent

    Jamie Smyth is the US pharmaceutical correspondent of the Financial Times. He is based in the New York bureau and covers the pharma and biotech sectors, drug discovery and healthcare issues such as the opioids crisis. He was previously Australia correspondent and Ireland correspondent.

    Before joining the FT Jamie worked as European correspondent for The Irish Times. He has a master’s degree in journalism from Dublin City University and a bachelor’s degree in history from Trinity College Dublin.

    Email Jamie Smyth @JamieSmythF  on Twitter (link opens in a new browser window)
    Email Jamie Smyth @JamieSmythF  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Sunday, 7 August, 2022
      Pharmaceuticals sector
      Merck defends tax approach against senator’s claims of avoidance

      Chief financial officer says drugmaker complies with law amid congressional probe

    • Saturday, 6 August, 2022
      Eli Lilly & Co
      Eli Lilly says Indiana abortion ban will shift jobs out of its home state

      Pharmaceutical company says new legislation will hinder its ability to attract diverse talent

    • Friday, 5 August, 2022
      Mergers & Acquisitions
      Pfizer in talks to buy Global Blood Therapeutics for roughly $5bn

      Big Pharma group is using cash pile from sales of Covid-19 vaccines to replenish drug pipeline

    • Thursday, 4 August, 2022
      Monkeypox
      US declares public health emergency over rapid spread of monkeypox

      Decision will allow Biden administration to tap new resources to combat disease amid criticism over its response

    • Wednesday, 3 August, 2022
      Reproductive rights
      Kansas voters reject anti-abortion amendment to state constitution

      Resounding victory for pro-choice campaign in first test of public opinion after Supreme Court ruling on Roe vs Wade

    • Tuesday, 2 August, 2022
      Monkeypox
      Biden appoints team to tackle fast-spreading monkeypox outbreak

      Move follows declarations of emergency by California and Illinois amid growing criticism of US government’s response

    • Tuesday, 2 August, 2022
      Roe vs Wade
      Kansas abortion vote tests public opinion after Supreme Court ruling

      Midwestern state is the first to let people weigh in on access to the procedure since Roe vs Wade was overturned

    • Monday, 1 August, 2022
      US Food & Drug Administration
      FDA halts UK group’s baby formula imports over ‘modified’ paperwork

      Supplies were intended to help with months-long shortage in America

    • Sunday, 31 July, 2022
      News in-depthRoe vs Wade
      US abortion pill boom raises legal and ethical questions

      Telehealth providers are stepping in to fill treatment gaps caused by the overturning of Roe vs Wade

    • Tuesday, 26 July, 2022
      3M Co
      3M earplugs unit files for bankruptcy amid lawsuits from military veterans

      US conglomerate known for Post-it notes and face masks will also spin off healthcare unit

    • Monday, 25 July, 2022
      Coronavirus treatment
      Slow uptake of Pfizer’s Covid drug hints at end to sales boom

      Paxlovid dominates antiviral treatment market but weak demand could cause supply glut, data group says

    • Thursday, 21 July, 2022
      Drug prices
      Pfizer and Flynn fined £70mn by UK regulator for epilepsy drug price rises

      Competition and Markets Authority cuts £20mn from previous penalty after long legal battle

    • Tuesday, 19 July, 2022
      Johnson & Johnson Co Inc
      J&J blames US dollar strength for second outlook cut in as many quarters

      Pharmaceutical group issues downbeat forecast despite better than expected quarterly results

    • Sunday, 10 July, 2022
      InterviewHow to Lead
      Moderna’s Noubar Afeyan on the race to create a Covid vaccine

      The chair of the $60bn US biopharma group explains how his approach to combining science with entrepreneurship led to the company’s creation

    • Friday, 8 July, 2022
      Covid-19 vaccines
      US rolls out Covid jabs for under-5s as others weigh up similar move

      European regulators consider vaccinating babies and toddlers, but some question the value of targeting youngsters

    • Sunday, 3 July, 2022
      Covid-19 vaccines
      Covid vaccines: how can immune imprinting help experts to rethink jabs?

      More than two years into the pandemic, people have acquired different levels of immunity through infections and shots

    • Thursday, 30 June, 2022
      US retail
      US baby formula crisis spurs debate over lack of competition

      Shortage following Abbott safety scandal draws scrutiny of sector dominated by just two companies

    • Wednesday, 29 June, 2022
      FT News Briefing podcast10 min listen
      A new legal battleground in US abortion wars

      UK advised to ban use of live facial recognition in public spaces

    • Tuesday, 28 June, 2022
      Covid-19 vaccines
      FDA panel recommends redesigning Covid vaccine to target Omicron variant

      Change would incorporate genetic material from fast-spreading strain in new boosters

    • Tuesday, 28 June, 2022
      Reproductive rights
      Abortion pills in demand after reversal of Roe vs Wade

      Remote providers report a leap in requests as conservative US states roll out a number of restrictions

    • Saturday, 25 June, 2022
      Covid-19 vaccines
      BioNTech/Pfizer say Omicron-targeting boosters elicit strong immune response

      New vaccine candidates significantly outperform existing Covid jabs at targeting the most prevalent strain

    • Thursday, 23 June, 2022
      Juul Labs
      FDA bans Juul products from US market in blow to e-cigarette maker

      Regulator cites teen vaping in decision against the country’s market leader

    • Wednesday, 22 June, 2022
      Moderna
      Moderna calls for approval of two-strain Covid vaccine booster

      US biotech group says shot targeting both first strain and Omicron could help avert ‘large rise’ in cases

    • Wednesday, 22 June, 2022
      Biotech
      Biotechs face ‘funding Sahara’ as easy money runs dry

      Early-stage drugmakers face difficult decisions as public markets turn hostile

    • Tuesday, 21 June, 2022
      Behind the Money podcast28 min listen
      Inside Johnson & Johnson’s bankruptcy two-step

      This legal manoeuvre is setting a new precedent for corporations to evade accountability in America

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT LiveFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2022. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      • Cryptofinance
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Community
      • FT Live
      • FT Forums
      • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In